Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Prescription savings platform GoodRx is collaborating with pharma giant Novo Nordisk to make Ozempic and Wegovy pens ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.

Novo Nordisk, the company that makes Ozempic, is now offering its popular diabetes drug to eligible patients for less than ...

Novo Nordisk reduces Ozempic's price to $499/month for self-paying patients, enhancing access to essential diabetes treatment ...

Several months after unveiling its direct-to-consumer NovoCare Pharmacy service with the launch of a $499 cash-pay option for ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk has announced a sweeping reduction in the cost of its blockbuster diabetes drug Ozempic, cutting the monthly ...